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Rationale: Assessment of mediastinal lymph nodes is recommended
in patients with non–small cell lung cancer without distant metasta-
ses. Linear transesophageal endoscopic ultrasound with real-time
guided fine-needle aspiration (EUS-FNA) is a promising, nonsurgical
tool for mediastinal staging.
Objectives: We conducted a randomized controlled trial comparing
surgical staging with EUS-FNA.
Methods: Patients with proven or suspected non–small cell lung
cancer in whom mediastinal exploration was required were ran-
domly assigned to undergo EUS-FNA or the appropriate surgical
staging procedure. When EUS-FNA did not show malignant lymph
node invasion, a confirmatory surgical staging procedure was done.
A negative surgical staging procedure was followed by thoracotomy
with systematic lymph node sampling. The primary endpoint was
the rate of surgical staging interventions. The secondary endpoints
were test performance of EUS-FNA and surgical staging, morbidity,
and length of hospital stay, considering surgical staging was per-
formed as an in-patient procedure.
MeasurementsandMainResults:Atotalof40patientswererandomized:
19 to EUS-FNA, and 21 to surgical mediastinal staging. Patient and
tumor characteristics were well balanced between both groups. For
patients allocated to EUS-FNA, surgical staging was needed in 32%
(P,0.001). The sensitivity to detect malignant lymph node invasion
was 93% (95% confidence interval, 66–99%) for EUS-FNA and 73%
(95% confidence interval, 39–93%) for surgical staging (P 5 0.29).
Complication rate was 0% for EUS-FNA and 5% for surgical staging
(P5 1.0). The median hospital stay was significantly shorter for EUS-
FNA than for surgical staging (0 vs. 2 nights; P, 0.001).
Conclusions: EUS-FNA reduces the need for surgical staging proce-
dures inpatientswith(suspected) lungcancer inwhomamediastinal
exploration is needed.
Clinical trial registered with www.clinicaltrials.gov (NCT 00119470).
Keywords: lung cancer; staging; mediastinoscopy; endoscopic ultra-
sound with fine-needle aspiration
In patients with non–small cell lung cancer (NSCLC) in whom
there is no evidence for extrathoracic metastasis, assessment of
the mediastinal lymph nodes for malignancy is of utmost impor-
tance (1–4). Mediastinal staging by surgical techniques (mainly
cervical mediastinoscopy) is considered the gold standard (5, 6),
although the sensitivity to detect malignant lymph node in-
vasion was shown earlier to be only 81% (7). In addition,
surgical staging is invasive, requires general anesthesia, and is
subject to potential serious complications (8).
Linear transesophageal endoscopic ultrasound with real-time
guided fine-needle aspiration (EUS-FNA) is a promising, mini-
mally invasive outpatient technique for the diagnosis and stag-
ing of mediastinal lymph nodes in patients with lung cancer.
Prospective series show a high sensitivity (0.72–1.00) and spec-
ificity (1.00) in computed tomography and/or positron emission
tomography (PET) scan–selected patients (9), document the ad-
vantage of rapid on site evaluation by a cytopathologist (10, 11),
and suggest that EUS-FNA could eliminate the need for surgery
in a substantial number of patients (12, 13).
We conducted a randomized, controlled trial comparing
surgical mediastinal staging with EUS-FNA in patients with
(suspected) NSCLC requiring mediastinal lymph node explora-
tion. We compared the number of surgical staging procedures,
hospital stay, number of lymph node stations assessed, compli-
cation rates, and test characteristics of both approaches.
METHODS
Patients
After approval of the study by the Medical Ethics Committee of the
Ghent University Hospital (study no. ECP2004276) and after protocol
registration (NCT 00119470), patients were recruited in December 2005
through January 2007 from the institutional thoracic oncology outpa-
tient clinic. Consent to perform all procedures (including thoracotomy)
in the Ghent University Hospital was required before screening. Eligible
patients had proven or suspected NSCLC, and had a suspected medi-
astinal lymph node invasion based on computed tomography and/or
fluorodeoxyglucose (FDG)-PET scan data. Our guidelines for invasive
mediastinal exploration were enlarged (>1-cm short axis) mediastinal
lymph nodes and/or FDG uptake in the mediastinal lymph nodes, tumors
abutting the mediastinum regardless of FDG uptake in the lymph nodes,
and absence of FDG uptake in the primary tumor (14, 15). In addition,
AT A GLANCE COMMENTARY
Scientific Knowledge on the Subject
Patient series have suggested that endoscopic ultrasound
with real-time guided fine-needle aspiration (EUS-FNA)
could reduce surgical staging of the mediastinum in lung
cancer. This has never been demonstrated prospectively
with a randomized, controlled trial comparing EUS-FNA
with the gold standard, surgical staging.
What This Study Adds to the Field
This randomized controlled trial shows that EUS-FNA
reduces the need for surgery, but also indicates its limi-
tations. The data implicate EUS-FNA can be used in
staging guidelines.
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the tumor had to be resectable, and the patients had to be functionally
operable. A multidisciplinary team approval preceded a possible in-
clusion. The selection criteria are shown in Table 1. Written informed
consent was obtained from all patients before enrolment. The patients
were randomly allocated between the following approaches: immediate
surgical staging (arm A—gold standard) and EUS-FNA, followed by
surgical staging in case of negative EUS-FNA result (arm B).
EUS-FNA
EUS-FNA was performed in an out-patient setting under local anesthe-
sia (with or without moderate sedation) using the curved linear scanning
ultrasound endoscope (GF-UCT160-OL5; Olympus, Aartselaar, Belgium)
connected to the ultrasound unit (Aloka, Mechelen, Belgium) (10), with
monitoring of heart rate and oxygen saturation (16). Punctures were
performed with a 22-gauge fine needle (EUS-needle; Olympus). Smears
of the aspirates obtained by EUS-FNA were processed on site to eval-
uate the cellular contents of the air-dried specimens with a quick-staining
method (Diff-Quick; Medion Diagnostics, Du¨dingen, Switzerland). If nec-
essary, several lymph nodes were sampled. Specimens were categorized
as positive (tumor cells), negative (lymphoid but no tumor cells), or not
representative (necrosis, no lymphoid cells). Punctures were continued
until the cytopathologist (L.R.V. or M.P.) was able to make a formal
conclusion.
Surgical Staging
Surgical staging for mediastinal exploration included cervical media-
stinoscopy, anterior mediastinotomy, video-assisted thoracoscopy, or
explorative thoracotomy, and was performed by dedicated thoracic
surgeons (F.D.R. or F.V.). The surgical technique for staging was
determined according to the preceding multidisciplinary team meet-
ing. For cervical mediastinoscopy, a systematic search of the lymph
node stations 2R/L, 4R/L, and 7 was performed (1, 8) according to the
Mountain-Dressler lymph node map (17). The sampled lymph nodes
were separately collected and stored for histological analysis. Accord-
ing to local practice, all patients undergoing surgical staging had at
least 1 night of postoperative observation.
Thoracotomy
In the case that no malignant lymph node invasion was shown with
either surgical staging or EUS-FNA followed by surgical staging, the
patient went for thoracotomy with systematic lymph node resampling
within 2 weeks (3, 15).
Data Collection
Data were obtained by the study coordinator during the visit at
baseline and at the time of subsequent intervention(s). Standardized
evaluation forms recording demographic characteristics, technical
investigations, and procedural characteristics, tumor and stage charac-
teristics, and data regarding admission to the hospital were noted.
Next, the data were transferred into an electronic database (Access;
Microsoft, Inc., Redmond, WA).
Outcome Measures and Statistical Analysis
Randomization (1:1) was performed based on an automated assign-
ment system generated before the study and only accessible by the
involved data managers. A stratification based on lymph node size was
applied to counter the possibility of lymph node size–dependent segre-
gation in one study arm, as large lymph nodes (arbitrarily designated as
having one axis of at least 2 cm) are technically easier to sample. The
primary outcome measure was the number of surgical interventions in
both study arms. A surgical procedure was considered avoided when it
did not occur after allocation to the EUS-FNA arm. Calculation of the
sample size was based on the estimated difference in the number of
surgical interventions needed for invasive mediastinal staging. Inclu-
sion of 20 patients in each arm was estimated to demonstrate a 40%
absolute reduction of surgical interventions with the use of the Fisher’s
exact test (power, 80%; type 1 error, 5%; two-sided testing). The sec-
ondary outcome measures were: evaluation of test characteristics
(sensitivity–specificity); complication rates; and length of hospital stay.
All endpoints were analyzed in the intention-to-treat (or to-diagnose)
population. For the analysis of the test characteristics, we took into
account only those patients in whom a formal mediastinal pathology
report was available. Continuous variables were compared using the
Mann-Whitney U test or Student’s t test, whereas categorical data were
compared with Fisher’s exact test. All data were analyzed with SPSS
15.0 (SPSS, Inc., Chicago, IL).
RESULTS
Enrollment and Baseline Characteristics of the Patients
We screened 44 patients, and 40 underwent randomization
(Figure 1). The demographic and clinical characteristics of the
patients in the two study groups were well balanced (Table 2).
Imaging of the mediastinum suggested N2 disease in 29 (73%)
and N3 in 11 (27%) subjects. PET data were available for 38
patients (95%), and suggested malignant lymph node invasion
(FDG uptake) in 33 (83%). A total of 25 patients (63%) had
proven NSCLC; in the others, there was a high clinical suspicion
based on their presentation and imaging studies.
Procedural Characteristics and Tumor Data
The surgical technique for staging the lymph nodes was cervical
mediastinoscopy in 20 patients and an anterior mediastinotomy
in 1 patient for a solitary paraaortic lymph node (lymph node
station 6) (Table 3). Both EUS-FNA and surgical staging pro-
cedures took about 35 minute to be completed. With EUS-FNA,
it was possible to observe the primary tumor in about one-third
of the cases, which was significantly more than with surgical
staging. Significantly more lymph nodes were sampled with
surgical techniques than with EUS-FNA.
The distribution of the primary lung tumor pathology shows
that the majority of the patients had NSCLC (Table 3).
However, four patients (10%) had small cell lung carcinoma.
In one patient, thoracotomy after a negative mediastinal evalu-
ation showed the presence of a benign schwannoma. The distri-
bution of tumor histology was comparable between the two
arms, as was the prevalence of malignant lymph node invasion.
Primary and Secondary Outcomes
The primary and secondary outcomes are summarized in Table
4. Surgical staging in the patients randomized to the EUS-FNA
arm occurred in 32%. This reflects a reduction of 68% of sur-
gical interventions for staging the mediastinum (primary endpoint,
P , 0.001).
TABLE 1. SELECTION CRITERIA
Category Description
Inclusion criteria Patients with a histological or cytological proof of NSCLC
or with a high clinical suspicion for lung cancer in whom
the next step is a surgical technique (cervical mediastino-
scopy, anterior mediastinotomy, thoracoscopy, or ex-
ploratory thoracotomy) formediastinal staging purposes.
No distant metastasis after routine clinical work up
(including optional FDG-PET scan)
Exclusion criteria Contraindications for esophageal endoscopy
(e.g., Zenker diverticle)
Contraindications for surgery (irresectable tumor or
inoperable patient)
Former therapy for lung cancer or concurrent other
malignancy
Definition of abbreviations: FDG 5 fluorodeoxyglucose; NSCLC 5 non–small
cell lung cancer; PET 5 positron emission tomography.
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No complications were noted in the patients investigated
with EUS-FNA. In the patient group randomized for surgical
staging, one esophageal perforation was noted. Other compli-
cations (e.g., infection or hoarseness) were not noted. Because
EUS-FNA is performed under local anesthesia as an outpatient
procedure, the length of hospital stay was significantly shorter
as compared with surgical staging techniques, which require
general anesthesia. The test characteristics were not different
between the staging approaches (Table 5). When calculating the
sensitivity of the surgical staging technique, also taking into
account the six patients of the EUS-FNA study arm who under-
went an additional surgical staging, the sensitivity becomes 75%
(95% confidence interval, 42–94%), which is also not statisti-
cally different from the value obtained with EUS-FNA only
(93%; 95% confidence interval, 66–99%).
DISCUSSION
This study shows that, in patients with (presumed) NSCLC
without extrathoracic metastasis, in whom mediastinal lymph
node exploration is required, EUS-FNA reduces the need for
surgical staging procedures by two-thirds (68%). We consider
this a relevant clinical benefit for the lung cancer patient, be-
cause implementation of EUS-FNA avoids the need for general
anesthesia and the potential complications associated with sur-
gical staging. At the time the current trial was designed (2004),
some retrospective and prospective series already suggested
a benefit of EUS-FNA for staging mediastinal lymph nodes in
lung cancer (18, 19). Larger series have since been published,
mainly focusing on the diagnostic performance of EUS-FNA in
the staging of lung cancer (10, 12, 20). These studies invariably
suggested a higher accuracy for EUS-FNA as compared with
imaging techniques, and reported on the reduction in the
number of surgical staging procedures. However, these studies
all had similar flaws in their lack of comparison with the current
standard of care (being surgical staging) (5, 6). These uncon-
trolled accuracy studies are important in the process of gener-
ating evidence of feasibility and effectiveness, but are, from
a conceptual point of view, not suited to provide information on
the difference between the gold standard and a new diagnostic
technique (21). Randomized studies are therefore of impor-
tance to study advancing diagnostic techniques beyond the level
of accuracy analyses. We are aware of only one published pro-
spective, randomized trial in this field, comparing EUS-FNA
with ‘‘conventional’’ diagnostic workup of patients with NSCLC
(22). The authors showed in their preliminary results that the
patients investigated with EUS-FNA had less futile thoracoto-
mies, the latter defined as explorative thoracotomy or recurrent
disease after resection. However, the design of that study makes
the interpretation of results difficult. Because the investigation
technique was tailored to the patient despite randomization,
EUS-FNA was performed in the majority of the patients. In
Figure 1. Study design–CONSORT (Con-
solidated Standards of Reporting Trials)
diagram. Patients were randomly as-
signed and staged, as per protocol, with
either a surgical technique or linear trans-
esophageal endoscopic ultrasound with
real-time guided fine-needle aspiration
(EUS-FNA) followed by a surgical tech-
nique when EUS-FNA was reported neg-
ative.
TABLE 2. DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF
PATIENTS AT RANDOMIZATION
Surgical Staging EUS-FNA
Variable (n 5 21) (n 5 19) P Value
Sex, n (%) 0.60
Male 20 (95) 17 (89)
Female 1 (5) 2 (11)
Age, mean (range), yr* 61 (42–74) 67 (47–78) 0.06
PET-CT, n (%) 20 (95) 18 (95) 1.00
FDG-positive MLN, n (%) 18 (90) 15 (83) 0.65
T stage at registration†, n (%) 1.00
cT1 2 (10) 1 (5)
cT2 16 (76) 16 (84)
cT3 1 (5) 0 (0)
cT4 2 (10) 2 (11)
N stage at registration‡, n (%) 0.49
cN2 14 (67) 15 (79)
cN3 7 (33) 4 (21)
N size (stratification), n (%) 1.00
Small, ,20 mm 11 (52) 9 (47)
Large, >20 mm 10 (48) 10 (53)
Aim of procedure, n (%) 0.10
Diagnosis and staging 5 (24) 10 (53)
Staging only (known NSCLC) 16 (76) 9 (47)
Definition of abbreviations: CT 5 computed tomography; EUS-FNA 5 linear
transesophageal endoscopic ultrasound with real-time guided fine-needle aspi-
ration; FDG 5 fluorodeoxyglucose; MLN 5 mediastinal lymph node; NSCLC 5
non–small cell lung cancer; PET 5 positron emission tomography.
* The difference between the mean age was compared with the Student’s
t test.
† Compared with Fisher’s exact test for cT1–cT2 vs. cT3–cT4. Some values add
up to 101% because of rounding.
‡ A mediastinal lymph node was considered suspect for invasion if its short axis
was 10 mm or greater measured on the CT scan, or if it accumulated FDG on the
PET-CT scan, regardless of its size. Mediastinal lymph nodes were also suspect if
the primary tumor did not accumulate FDG, if the tumor was centrally located, or
if hilar lymph nodes were FDG positive (see METHODS).
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addition, there are several methodological differences: EUS-
FNA was variably performed under general anesthesia, and
there was no on-site evaluation of the samples. The latter has
been shown to be valuable for EUS-FNA, especially when
performed by a dedicated cytopathologist (10, 11).
In the present study, patients were all candidates for radical
surgery after a diagnostic work-up adhering to the available
guidelines. Furthermore, and in contrast with previous series,
the pathology assessment of the mediastinal lymph nodes was
strictly defined. As such, we provide solid evidence that EUS-
FNA should be implemented in the preoperative staging
algorithm of patients with (presumed) lung cancer who have
no evidence of extrathoracic metastasis. In addition, the current
data show that the implementation of EUS-FNA in the staging
algorithm of lung cancer results in less complications and a
shorter hospital stay as compared with conventional staging.
However, the latter statement might not be applicable when
surgical staging is performed as an outpatient procedure (23–25).
No difference was found in the diagnostic performance
between study arms. Although the sensitivity of rapid on-site
examination–assisted EUS-FNA to detecting malignant lymph
node invasion tended to be higher than that with surgical
staging (10, 26), this difference was not statistically significant,
even when taking into account the patients who underwent both
procedures. Together, the present data are in agreement with
the test characteristics that have been published for these
techniques (7), and indicate that implementing EUS-FNA does
not result in a lower sensitivity. The negative predictive value of
EUS-FNA is too low to preclude further lymph node sampling
in case of a negative result. This is in agreement with published
data (12). The results of the present study do not allow a
conclusion about the preferred diagnostic method in the case of
negative EUS-FNA. Because it was shown, in a prospective
series, that the combination of mediastinoscopy and EUS-FNA
improves the sensitivity and negative predictive value (27), we
opted to use a mediastinoscopy before referring the patient to
thoracotomy. It is impossible to rule out false-positive findings
either for EUS-FNA or for surgical staging procedures. This is
related to the current study design. However, it seems reason-
able to assume that the false-positive rate is low in mediastinal
staging (6), although one study showed that sampling a left
lower lobe tumor instead of a mediastinal lymph node might
result in overstaging (27).
Another finding with potential implications is a difference
in the completeness of mediastinal staging between the two
studied techniques, as the number of sampled lymph nodes was
significantly lower in the patients investigated only with EUS-
FNA. This has to do with the anatomy of the mediastinum and
the interposition of the trachea impeding the investigation of
solitary lymph nodes located strictly in the lower right-sided
paratracheal area (region 4R). A weakness of this study lies in
EUS-FNA missing malignant N3 invasion whenever only N2 is
shown. However, this has no implication for treatment alloca-
tion, as combination chemoradiotherapy, especially delivered
concurrently, is the preferred treatment for locally advanced
NSCLC, regardless of the level of mediastinal lymph node
involvement (28). Moreover, even if one should consider
surgery after induction chemotherapy for IIIA NSCLC, invasive
restaging of the mediastinum is currently advocated. Remedias-
tinoscopy has been shown to be inaccurate (29), which is an
additional reason for assessing the mediastinum with minimally
invasive techniques before any treatment is given.
TABLE 3. DESCRIPTION OF THE STAGING PROCEDURES AND
TUMOR AND LYMPH NODE CHARACTERISTICS
Surgical Staging EUS-FNA
Characteristic (n 5 21) (n 5 19) P Value
Type of surgical staging 1.00
Cervical mediastinoscopy 20 (95) 6 (100)
Anterior mediastinotomy 1 (5) 0 (0)
Procedure duration; median (range), min 35 (20–120) 35 (20–75) 0.61
T stage 0.04
Primary tumor observed, n (%) 1 (5) 6 (32)
N stage
No. of MLN seen; median (range) NA 2 (1–4) NA
Enlarged MLN with EUS, n (%)* NA 18 (90) NA
No. of MLN sampled, median (range)† 4 (1–5) 1 (1–3) ,0.0001
Cancer type‡
Squamous cell 9 (45) 7 (37) 1.00x
Nonsquamous 10 (50) 9 (47)
Small cell 1 (5) 3 (16) 0.34k
MLN status{
Malignant 11 (58) 14 (74) 0.50
Benign 8 (42) 5 (26)
N2/N3 7/4 11/3 0.66
Definition of abbreviations: EUS/FNA 5 linear transesophageal endoscopic
ultrasound with real-time guided fine-needle aspiration; MLN 5 mediastinal
lymph node; NA 5 not applicable.
* Defined as a short axis of at least 10 mm.
† MLN stations sampled for mediastinal staging (before thoracotomy)
‡ Upon resection, one patient with presumed non–small cell lung cancer
(NSCLC) had not a carcinoma, but a benign schwannoma.
x The distribution was comparable between squamous and nonsquamous lung
cancers.
k The distribution was comparable between NSCLC and small cell lung cancer.
{ Two patients had a negative mediastinoscopy, but underwent neither a
thoracotomy, nor a systematic LN sampling. These patients were not taken into
account here. In one patient in whom the surgical staging was negative,
EUS-FNA instead of thoracotomy was performed, demonstrating NSCLC in
MLN 4L.
TABLE 4. OUTCOMES OF ULTRASOUND AND SURGICAL
STAGING: PRIMARY AND SECONDARY ENDPOINTS
Surgical Staging EUS-FNA
Procedure Variable (n 5 21) (n 5 19) P Value
Surgical staging procedure, n (%)
No 0 (0) 13 (68) ,0.0001
Yes 21 (100) 6 (32)
Complications, n (%)*
Perforation/bleeding 1 (5) 0 (0) 1.00
Hospital stay, nights, median (range)† 2 (1–22) 0 (0–5) ,0.0001
For definition of abbreviations, see Table 3 footnote.
* One esophageal perforation.
† Hospital stay for staging only. All patients staged with EUS-FNA as a single
procedure were investigated as an outpatient procedure. The figure for the EUS-
FNA arm includes the hospitalization for the subsequent surgical staging in case
this was required.
TABLE 5. ANALYSIS OF TEST CHARACTERISTICS ACCORDING TO
ALLOCATED APPROACH
Surgical Staging* EUS-FNA
Characteristics (n 5 19) (n 5 19) P Value
Sensitivity 73 (39–93) 93 (66–99) 0.29
Specificity 100 (69–100) 100 (47–100) NA
Positive predictive value 100 (63–100) 100 (75–100) NA
Negative predictive value 73 (39–93) 83 (35–99) 1.00
For definition of abbreviations, see Table 3 footnote.
* Two patients had an unconfirmed negative mediastinoscopy and were not
included in this analysis (see METHODS).
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Nevertheless, early data based on selected patients suggest
that endobronchial ultrasound with real-time guided transbron-
chial needle aspiration could overcome the problem of incom-
plete mediastinal sampling (30–32). Whether the combination
of this method and EUS-FNA will become an alternative for
overcoming the aforementioned problem is currently under
investigation (32, 33).
Based on the outcomes of this study, we conclude that EUS-
FNA reduces the need for surgical staging procedures in patients
with (suspected) lung cancer in whom a mediastinal exploration
is needed. Therefore, we propose that, in these patients, the
mediastinum should be first investigated with EUS-FNA, fol-
lowed by surgical staging in the case of negative findings.
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